NCT05514938View on ClinicalTrials.gov

Polypill in Acute Coronary Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 30, 2022

Primary Completion Date

May 30, 2025

Study Completion Date

June 5, 2025

Conditions
Acute Coronary SyndromeLipid DisorderCoronary Artery Disease
Interventions
DRUG

Polypill

Polypill formulation consisting of rosuvastatin, aspirin, and prasugrel or consisting of rosuvastatin, aspirin, and clopidogrel.

DRUG

Usual Care (individual medications prescribed by primary cardiologist)

Typical prescriptions for post-acute coronary syndrome care including statin, aspirin, and prasugrel or clopidogrel.

Trial Locations (1)

75235

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER